Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-02-13

Clinical Trial Update: A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas [Phase 2]

View source ↗

Summary

A Phase II trial evaluating pegylated interferon alfa-2b in pediatric diffuse intrinsic pontine glioma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PegIntron (pegylated interferon alfa-2b)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Intrinsic Pontine Glioma | Phase 2 | Status: COMPLETED | Results posted: 2012-02-13